Sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats

Epilepsia

Volumn 55, Issue 12, 2014, Pages 1953-1958

  Bar Klein, Guy ^a   Swissa, Evyatar ^a   Kamintsky, Lyn ^a   Shekh Ahmad, Tawfeeq ^b   Saar Ashkenazy, Rotem ^a   Hubary, Yechiel ^c   Shrot, Shai ^d   Stetlander, Liran ^d   Eisenkraft, Arik ^b,c,d   Friedman, Alon ^a   Bialer, Meir ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c Ministry of Defence Government of Israel   (Israel)

^d MEDICAL CORPS   (Israel)

Author keywords

New antiepileptic drugs; Paraoxon induced SE rat model; sec Butyl propylacetamide; Status epilepticus; Valproic acid amide derivative

Indexed keywords

ANTICONVULSIVE AGENT; ATROPINE; MIDAZOLAM; OBIDOXIME; PARAOXON; SEC BUTYL PROPYLACETAMIDE; UNCLASSIFIED DRUG; VALNOCTAMIDE; VALPROIC ACID DERIVATIVE; AMIDE; INSECTICIDE; SEC-BUTYL-PROPYLACETAMIDE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ELECTROCORTICOGRAPHY; EPILEPTIC STATE; LD 50; MALE; NONHUMAN; RAT; SEIZURE; STEREOISOMERISM; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; ELECTROENCEPHALOGRAPHY; NONPARAMETRIC TEST; SPRAGUE DAWLEY RAT; STATUS EPILEPTICUS; TOXICITY; TREATMENT OUTCOME;

AMIDES; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; INSECTICIDES; MALE; PARAOXON; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC; STATUS EPILEPTICUS; STEREOISOMERISM; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84919958050     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12838     Document Type: Article

References (34)

1. Rosman Y, Eisenkraft A, Milk N, et al. Lessons learned from the Syrian sarin attack: evaluation of a clinical syndrome through social medialessons learned from the Syrian sarin attack. Ann Intern Med 2014; 160: 644-648.
2. Antonijevic B, Stojiljkovic MP,. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin Med Res 2007; 5: 71-82.
3. Jokanovic M, Stojiljkovic MP,. Current understanding of the application of pyridinium oximes as cholinesterase reactivators in treatment of organophosphate poisoning. Eur J Pharmacol 2006; 553: 7-10.
4. Marrs TC,. Organophosphate poisoning. Pharmacol Ther 1993; 58: 51-66.
5. Cannard K,. The acute treatment of nerve agent exposure. J Neurol Sci 2006; 249: 86-94.
6. Hulse EJ, Clutton RE, Drummond G, et al. Translational toxicological research: investigating and preventing acute lung injury in organophosphorus insecticide poisoning. J R Army Med Corps 2013; 160: 191-192.
7. Eisenkraft A, Falk A, Finkelstein A,. The role of glutamate and the immune system in organophosphate-induced CNS damage. Neurotox Res 2013; 24: 265-279.
8. Malekirad AA, Faghih M, Mirabdollahi M, et al. Neurocognitive, mental health, and glucose disorders in farmers exposed to organophosphorus pesticides. Arh Hig Rada Toksikol 2013; 64: 1-8.
9. Shrot S, Ramaty E, Biala Y, et al. Prevention of organophosphate-induced chronic epilepsy by early benzodiazepine treatment. Toxicology 2014; 323: 19-25.
10. Delgado-Escueta AV, Bajorek JG,. Status epilepticus: mechanisms of brain damage and rational management. Epilepsia 1982; 23: 29-41.
11. McDonough JH, McLeod CG, Nipwoda MT,. Direct microinjection of soman or VX into the amygdala produces repetitive limbic convulsions and neuropathology. Brain Res 1987; 435: 123-137.
12. Zilker T,. Medical management of incidents with chemical warfare agents. Toxicology 2005; 214: 221-231.
13. Jones DM, Esmaeil N, Maren S, et al. Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res 2002; 50: 301-312.
14. Bourgeois BFD,. Chronic management of seizures in the syndromes of idiopathic generalized epilepsy. Epilepsia 2003; 44 (Suppl. 2): 27-32.
15. Brodie MJ,. Management strategies for refractory localization-related seizures. Epilepsia 2001; 42 (Suppl. 3): 27-30.
16. Löscher W,. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16: 669-694.
17. Bialer M, Yagen B,. Valproic acid: second generation. Neurotherapeutics 2007; 4: 130-137.
18. Bialer M, White HS,. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 2010; 9: 68-82.
19. Hen N, Shekh-Ahmad T, Yagen B, et al. Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. J Med Chem 2013; 56: 6467-6477.
20. White HS, Alex AB, Pollock A, et al. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 2012; 53: 134-146.
21. Pouliot W, Bialer M, Hen N, et al. A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience 2013; 231: 145-156.
22. Kaufmann D, Bialer M, Shimshoni JA, et al. Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. J Med Chem 2009; 52: 7236-7248.
23. Bar-Klein G, Cacheaux LP, Kamintsky L, et al. Losartan prevents acquired epilepsy via TGF-β signaling suppression. Ann Neurol 2014; 75: 864-875.
24. Whitney AW,. A direct method of nonparametric measurement selection. IEEE Trans Comput C 1971; 20: 1100-1103.
25. Rumelhart DE, Hinton GE, Williams RJ,. Learning representations by back-propagating errors. Nature 1986; 323: 533-536.
26. Powell MJD,. Restart procedures for the conjugate gradient method. Math Program 1977; 12: 241-254.
27. Racine RJ,. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972; 32: 281-294.
28. Loddenkemper T, Goodkin HP,. Treatment of pediatric status epilepticus. Curr Treat Options Neurol 2011; 13: 560-573.
29. Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59: 205-222.
30. Cavalheiro EA, Santos NF, Priel MR,. The pilocarpine model of epilepsy in mice. Epilepsia 1996; 37: 1015-1019.
31. Carpentier P, Delamanche IS, Le Bert M, et al. Seizure-related opening of the blood-brain barrier induced by soman: possible correlation with the acute neuropathology observed in poisoned rats. Neurotoxicology 1990; 11: 493-508.
32. Levy RH, Boddy AV,. Stereoselectivity in pharmacokinetics: a general theory. Pharm Res 1991; 8: 551-556.
33. Tucker GT,. Chiral switches. Lancet 2000; 355: 1085-1087.
34. Agranat I, Caner H, Caldwell J,. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 2002; 1: 753-768.